| Trial | Treatments | Patients | Method |
|---|
| ISIS-4, 1995 | captopril 6.25mg twice daily initialy titrated up to 50 mg twice daily (for 1 month) (n=29028) vs. placebo (n=29022) | Acute MI <24h of MI, no cardiogenic shock or persistent severe hypotension | double blind Factorial plan Sample size: 29028/29022 Primary endpoint: death FU duration: 1 month |
| CCS-1, 1995 | captopril6.25 mg initial dose, 12.5 mg 2 h later, and then 12.5 mg three times daily for 28 days (n=13634) vs. placebo (n=0) | Acute MI <36h of MI | double blind Parallel groups Sample size: 13634/0 Primary endpoint: death FU duration: 1 month |
| SAVE, 1992 | Captopril 12·5 mg initial dose, up to 25–50 mg three times daily (n=1115) vs. placebo (n=1116) | patient within 3–16 days of a MI, LVEF <40% | double blind Parallel groups Sample size: 1115/1116 Primary endpoint: Mortality from all causes FU duration: 3.5y |
| Pfeffer, 1988 | Captopril (n=38) vs. placebo (n=0) | patient within 11-31 days after MI, LVEF<=45%, not in overt congestive heart failure | double blind Parallel groups Sample size: 38/0 Primary endpoint: hemodynamic function and left ventricular volume FU duration: 1 year |
| Sogaard, 1994 | Captopril 50mg daily (n=58) vs. placebo (n=0) | patients with left ventricular (LV) dysfunction on day 7 after MI | double blind Parallel groups Sample size: 58/0 Primary endpoint: Ventricular arrhythmias FU duration: 6 months |
| Sharpe, 1988 | Captopril 25 mg thrice a day (n=60) vs. placebo (n=0) | patients with symptomless left ventricular dysfunction (LVEF<45%) 1 week after a myocardial infarction without clinical evidence of heart failure | double blind Parallel groups Sample size: 60/0 Primary endpoint: left ventricular volumes FU duration: 1 year |
| Mortarino, 1990 | Captopril 25 mg bid (n=10) vs. placebo (n=11) | patient with mild congestive heart failure after recent MI | double blind Parallel groups Sample size: 10/11 Primary endpoint: none FU duration: 2 months |
| French, 1999 | captopril 6.25 mg, increasing to 50 mg t.d.s. (n=243) vs. placebo (n=250) | patients aged < or = 75 years with first infarctions, presenting within 4 h of symptom onset | double blind Parallel groups Sample size: 243/250 Primary endpoint: regional wall motion FU duration: 1 year |
| CATS, 1996 | captopril 25 mg three times a day (n=149) vs. placebo (n=149) | patients with a first anterior myocardial infarction treated with intravenous streptokinase within 6h of onset of symptoms | double blind Parallel groups Sample size: 149/149 Primary endpoint: left ventricular volume index FU duration: 1 year |
| PRACTICAL (captopril), 1994 | captopril 25 mg three times daily or enalapril 5 mg three times daily (n=150) vs. placebo (n=75) | patients with acute myocardial infarction within 24 hours of onset | double blind Parallel groups Sample size: 150/75 Primary endpoint: LV function FU duration: 1 year |
| ECCE, 1997 | captopril titrated dose in order to preserve their blood pressure (n=104) vs. placebo (n=104) | patients with acute myocardial infarction | double blind Parallel groups Sample size: 104/104 Primary endpoint: exercise testing FU duration: 1 month |
| Sharpe, 1991 | captopril 50 mg twice daily (n=100) vs. placebo (n=0) | patients with Q wave myocardial infarction, but without clinical heart failure 24-48h after onset of symptoms | double blind Parallel groups Sample size: 100/0 Primary endpoint: Left ventricular volumes FU duration: 3 months |
| Ray, 1993 | captopril 25 mg three times a day (n=99) vs. placebo (n=0) | haemodynamically stable patients with acute myocardial infarction, selected on clinical grounds as being at risk of late ventricular dilatation | double blind Parallel groups Sample size: 99/0 Primary endpoint: none FU duration: 1 year |
| Nabel, 1991 | intravenous followed by oral captopril (n=20) vs. placebo (n=18) | patients with myocardial infarction | double blind Parallel groups Sample size: 20/18 Primary endpoint: none FU duration: 3 months |
| Bussmann, 1992 | slow intravenous bolus injection of 2.5 or 5.0 mg captopril followed by a continuous infusion of 1.5-2.0 mg/h for a period of 48 hours (n=22) vs. placebo (n=24) | patients with acute myocardial infarction | double blind Parallel groups Sample size: 22/24 Primary endpoint: QRS complexes FU duration: 48h |
| Di Pasquale, 1994 | captopril, 6.25 mg, orally 15 min before thrombolysis (n=188) vs. placebo before thrombolysis (n=183) | patients with acute myocardial infarction , hospitalized within 4 h of the onset of symptoms | double blind Parallel groups Sample size: 188/183 Primary endpoint: not defined FU duration: 2h |
| Di Pasquale, 1997 | captopril first dose 2-4 h after starting thrombolysis (the dose was then increased up to 25 mg every 8 h (n=31) vs. placebo (n=30) | patients hospitalized for suspected anterior AMI within 4 h from the onset of symptoms suitable for thrombolysis | double blind Parallel groups Sample size: 31/30 Primary endpoint: not defined FU duration: 12h |
| Galcera, 1993 | captopril (n=21) vs. placebo (n=22) | patients with a first acute myocardial infarction and a pulmonary capillary pressure equal or above 17 mmHg | double blind Parallel groups Sample size: 21/22 Primary endpoint: left ventricular volume indexes FU duration: 14 days |
| Hargreaves, 1992 | 12.5 mg of captopril three times daily (n=36) vs. placebo (n=36) | patients with acute myocardial infarction (systolic blood pressure > 90 mm Hg) within 24 hours of the start of pain | double blind Parallel groups Sample size: 36/36 Primary endpoint: none defined FU duration: 28 days |
